Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...

The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...

Kikuchi–Fujimoto disease (KFD), histiocytic necrotising lymphadenitis, is a benign and self-limiting disease characterised ...

Together with GSK, the Boston-based research team will ... pulmonary disease, amyloidosis, and dermatology, among other areas. The school’s 30 teaching affiliates include Boston Medical Center ...

Johnson & Johnson announced at its booth the China market launch of INVEGA HAFYERA, a medicine for the treatment of ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Maternal hidradenitis suppurativa (HS) was associated with ...

including EASI-75 and IGA 0/1 Enrollment included approximately 15% of patients with Dupixent/anti-IL-13 treatment experience Presented analyses that characterize a BTLA transcriptomic signature in AD ...

From dermatology to pain management and beyond ... The major players in the market are Hisamitsu Pharmaceuticals, Bayer AG, Novartis AG, Galderma Holding SA, GlaxoSmithKline PLC, Johnson & Johnson ...

GlaxoSmithKline Pharmaceuticals Limited is ... such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases. They also offer a range ...